CA2286349A1 - Elaboration de proteines fonctionnelles : equilibre entre contrainte tangentielle et gravite - Google Patents
Elaboration de proteines fonctionnelles : equilibre entre contrainte tangentielle et gravite Download PDFInfo
- Publication number
- CA2286349A1 CA2286349A1 CA002286349A CA2286349A CA2286349A1 CA 2286349 A1 CA2286349 A1 CA 2286349A1 CA 002286349 A CA002286349 A CA 002286349A CA 2286349 A CA2286349 A CA 2286349A CA 2286349 A1 CA2286349 A1 CA 2286349A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- shear stress
- culture
- renal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé relatif à l'élaboration de protéines fonctionnelles, y compris les hormones issues des cellules rénales, qui consiste à établir un processus de co-culture à trois dimensions réagissant à la contrainte tangentielle dans un récipient à parois tournantes. Le mélange naturel des cellules rénales exprime l'enzyme 1-a-hydroxylase, susceptible d'être utilisée pour engendrer la forme active de la vitamine D: 1,25-diOH vitamine D3. Les cultures de fibroblastes et la co-culture de cellules rénales corticales expriment le gène correspondant à l'érythropoïétine et secrètent l'érythropoïétine dans le surnageant de culture. D'autres gènes réagissant à la contrainte tangentielle sont également modulés sous l'effet de ladite contrainte : par exemple, récepteurs de toxines comme la mégaline et la cubuline (gp280). L'invention concerne aussi un procédé conçu pour traiter les individus nécessitant un traitement à base de protéines fonctionnelles, élaborées en processus de co-culture à trois dimensions réagissant à la contrainte tangentielle et établi dans un récipient à parois tournantes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4320597P | 1997-04-08 | 1997-04-08 | |
US60/043,205 | 1997-04-08 | ||
PCT/US1998/006826 WO1998045468A1 (fr) | 1997-04-08 | 1998-04-07 | Elaboration de proteines fonctionnelles : equilibre entre contrainte tangentielle et gravite |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2286349A1 true CA2286349A1 (fr) | 1998-10-15 |
Family
ID=21926026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002286349A Abandoned CA2286349A1 (fr) | 1997-04-08 | 1998-04-07 | Elaboration de proteines fonctionnelles : equilibre entre contrainte tangentielle et gravite |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0972069A1 (fr) |
JP (1) | JP2001517081A (fr) |
AU (1) | AU6953498A (fr) |
BR (1) | BR9808510A (fr) |
CA (1) | CA2286349A1 (fr) |
IL (1) | IL132264A0 (fr) |
WO (1) | WO1998045468A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002533113A (ja) * | 1998-12-24 | 2002-10-08 | フローレンス・メディカル・リミテッド | 複数の剪断応力応答配列(ssre)および目的の遺伝子を含む発現ベクター、およびその使用法 |
AU2005270968A1 (en) * | 2004-08-04 | 2006-02-16 | Merck Serono Sa | Capsules containing transfected cells, method for preparing the same and uses thereof for immunization and vaccination |
JP5350364B2 (ja) * | 2007-04-28 | 2013-11-27 | ヒョンジン ヤン, | 粉末状の足場を用いた細胞間の信号調節による細胞培養方法 |
EP2454373B1 (fr) * | 2009-07-15 | 2014-11-19 | AbbVie Inc. | Augmentation de la production cellulaire par transduction mecanique |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4988623A (en) * | 1988-06-30 | 1991-01-29 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Rotating bio-reactor cell culture apparatus |
WO1991011535A1 (fr) * | 1990-01-30 | 1991-08-08 | Childrens Hospital Of Los Angeles | Inhibition de transcription a l'aide d'oligonucleotides bicatenaires |
-
1998
- 1998-04-07 JP JP54098398A patent/JP2001517081A/ja not_active Ceased
- 1998-04-07 IL IL13226498A patent/IL132264A0/xx unknown
- 1998-04-07 AU AU69534/98A patent/AU6953498A/en not_active Abandoned
- 1998-04-07 CA CA002286349A patent/CA2286349A1/fr not_active Abandoned
- 1998-04-07 EP EP98915320A patent/EP0972069A1/fr not_active Withdrawn
- 1998-04-07 WO PCT/US1998/006826 patent/WO1998045468A1/fr not_active Application Discontinuation
- 1998-04-07 BR BR9808510-7A patent/BR9808510A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2001517081A (ja) | 2001-10-02 |
EP0972069A1 (fr) | 2000-01-19 |
BR9808510A (pt) | 2000-05-23 |
WO1998045468A1 (fr) | 1998-10-15 |
AU6953498A (en) | 1998-10-30 |
IL132264A0 (en) | 2001-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7972821B2 (en) | Production of functional proteins: balance of shear stress and gravity | |
Kaysen et al. | Select de novo gene and protein expression during renal epithelial cell culture in rotating wall vessels is shear stress dependent | |
CN107743522A (zh) | 类血管生成素3(ANGPTL3)iRNA组合物及其使用方法 | |
CN108368507A (zh) | 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法 | |
KR20160009687A (ko) | Tmprss6 조성물 및 이의 사용 방법 | |
IL194419A (en) | Dsrna to inhibit the expression of a 5eg gene in a human cell, a pharmaceutical compound containing it, a vector method | |
EP2077326A1 (fr) | Nouvel acide nucléique | |
US6730498B1 (en) | Production of functional proteins: balance of shear stress and gravity | |
CN111110855A (zh) | 一种利用红细胞制备的靶向性的囊泡药物 | |
CN113710811B (zh) | T细胞基因表达的非病毒修饰 | |
US20030143742A1 (en) | Compositions for receptor/liposome mediated transfection and methods of using same | |
Jeong et al. | Exosome-based antisense locked nucleic acid delivery for inhibition of type II collagen degradation in chondrocyte | |
US9163234B2 (en) | Culture method | |
US20230287408A1 (en) | Nucleic acid constructs for delivering polynucleotides into exosomes | |
CA2286349A1 (fr) | Elaboration de proteines fonctionnelles : equilibre entre contrainte tangentielle et gravite | |
KR101170473B1 (ko) | 신규한 리피드?금나노입자 복합체 및 상기 복합체를 이용한 유전자 등의 생리활성물질의 전달 방법 | |
EP0733640B1 (fr) | Oligonucleotide bicatenaire et agent carcinostatique le contenant en tant que constituant actif | |
US11466272B2 (en) | Nucleic acid suppressing expression of APCS | |
WO2022054801A1 (fr) | ARNsi ET SON UTILISATION | |
MXPA99009265A (en) | Production of functional proteins:balance of shear stress and gravity | |
JP2000506866A (ja) | アンギオテンシノゲンmRNAに標的化されたオリゴヌクレオチド | |
CN112639113A (zh) | 核酸递送载体、核酸递送载体组、核酸递送组合物和核酸递送方法 | |
Pichu et al. | Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes | |
JPWO2005054486A1 (ja) | 遺伝子導入試薬調製法 | |
CN116036019A (zh) | 一种含负电荷脂质的核酸递运系统 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |